ArticleBMC psychiatry2025
Investigation of the correlation between urinary aromatic amines and the risk of depression through an examination of the NHANES data from 2013 to 2014.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe relationship between aromatic amines (AA)s and depressive disorder remains elusive. The aim of this investigation was to examine the potential link between urinary AA levels and the likelihood of depression in American adults.
methodsThrough the analysis of data from 1175 participants in the 2013-2014 NHANES, our study delved into the association between urinary AA levels and the incidence of depression. Assessment of depression severity was conducted using the PHQ-9 questionnaire, alongside measuring levels of six urinary AAs. We explored this correlation in the overall population and various subgroups by employing a multivariable logistic model, restricted cubic spline (RCS) analysis, and a sensitivity analysis model while adjusting for potential confounding variables.
resultsParticipants diagnosed with depression exhibited elevated levels of 1-Aminonaphthalene, 2-Aminonaphthalene and 2,6-Dimethylaniline compared to non-depressed individuals. Specifically, the presence of 2-Aminonaphthalene was correlated with an elevated likelihood of depression in continuous and categorical models (OR: 1.013, CI: 1.004-1.023, p = 0.006; Q4 vs. Q1: OR: 1.687, CI: 1.015-2.805, p = 0.037) after fully adjusted for gender, RIP, education level, BMI, smoking, hypertension and diabetes. The likelihood of depression showed a statistically significant linear dose-response relationship with 2-Aminonaphthalene (P
conclusionElevated levels of certain amino acids in urine were associated with a higher likelihood of depression. Notably, 2-aminonaphthalene appeared to be a significant contributing factor, particularly among smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.